0
Abstract: Slide Presentations |

LONG-TERM TREATMENT WITH SITAXSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (PAH-CTD) FREE TO VIEW

Reda E. Girgis, MD*; Adaani Frost, MD; Nick Hill, MD; David Langleben, MD; Vallerie McLaughlin, MD; Ron Oudiz, MD; Terrance Coyne, MD
Author and Funding Information

Johns Hopkins University, Baltimore, MD


Chest


Chest. 2005;128(4_MeetingAbstracts):218S. doi:10.1378/chest.128.4_MeetingAbstracts.218S
Text Size: A A A
Published online

Abstract

PURPOSE:  PAH-CTD is progressive, difficult to manage, and the leading cause of death in CTD. Endothelin levels are increased in PAH-CTD and have vasoconstrictive and proliferative effects primarily mediated by the smooth muscle cell ETA receptor. Sitaxsentan (SITAX) is a pharmacologically distinct, oral, once-daily, highly selective (6500:1) endothelin ETA receptor antagonist. We previously reported that PAH-CTD patients (pts) in STRIDE-1, a 12 wk, MC, DB, placebo (PBO) controlled trial improved 6MW (58m; p=0.0274), NYHA functional class (NYHA FC) and hemodynamics. For the first time, we report on the long-term follow-up of the PAH-CTD subgroup during the STRIDE-1X extension study.

METHODS:  STRIDE-1 evaluated SITAX 100mg, 300 mg, and PBO. Due to similar treatment effects in total ITT population, the SITAX 100mg and 300mg groups were pooled. After STRIDE-1, pts could enter the blinded STRIDE-1X and were treated with either SITAX 100mg or 300mg. Pts on PBO were re-randomized to either SITAX 100mg or 300mg. NYHA FC data were collected in STRIDE-1X. A post hoc analysis was performed to evaluate the effect of SITAX in the intent-to-treat PAH-CTD subgroup. At baseline, 42 of 178 pts had PAH-CTD and were NYHA FC II or III. 41 pts entered STRIDE-1X.

RESULTS:  Median and mean treatment was 26 weeks, maximum 55 weeks. Overall, 22 (54%) pts improved by more than one NYHA FC with 11 (50%) pts reporting first improvement during the week 0-12 and 11 (50%) during week 12-52. Two (5%) pts deteriorated by one or more NYHA FC, both occuring by week 4. Both doses of sitaxsentan were well tolerated. One pt (5%) in each group reported liver function abnormalities >3xULN during the entire treatment course. 5 pts discontinued during the study.

CONCLUSION:  Short-term treatment with SITAX improves NYHA FC. First time improvements in NYHA FC may also occur late in treatment. Long-term treatment with SITAX is well tolerated.

CLINICAL IMPLICATIONS:  SITAX has a favorable safety and efficacy profile in pts with PAH-CTD.

DISCLOSURE:  Reda Girgis, Grant monies (from industry related sources) Encysive Pharmaceuticals; Consultant fee, speaker bureau, advisory committee, etc. Encysive Pharmaceuticals; Product/procedure/technique that is considered research and is NOT yet approved for any purpose. sitaxsentan.

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543